Context Begin Period Cash Flow vs Change In Working Capital Analysis

CNTX Stock

USD 1.01 0.03 3.06%

Context Therapeutics financial indicator trend analysis is way more than just evaluating Context Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Context Therapeutics is a good investment. Please check the relationship between Context Therapeutics Begin Period Cash Flow and its Change In Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Context Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Begin Period Cash Flow vs Change In Working Capital

Begin Period Cash Flow vs Change In Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Context Therapeutics Begin Period Cash Flow account and Change In Working Capital. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Context Therapeutics' Begin Period Cash Flow and Change In Working Capital is 0.4. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change In Working Capital in the same time period over historical financial statements of Context Therapeutics, assuming nothing else is changed. The correlation between historical values of Context Therapeutics' Begin Period Cash Flow and Change In Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Context Therapeutics are associated (or correlated) with its Change In Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Working Capital has no effect on the direction of Begin Period Cash Flow i.e., Context Therapeutics' Begin Period Cash Flow and Change In Working Capital go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Most indicators from Context Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Context Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Context Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.Selling General Administrative is likely to rise to about 9.1 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 31 M in 2025.

Context Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Good Will	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Debt	Non Current Assets Total
Total Assets		0.07	-0.6	0.97	0.31	-0.12	-0.46	-0.41	0.98	0.34	0.07	0.08	0.53	0.0	-0.59	0.34	-0.54	-0.03	0.97	-0.57	0.08	0.48	0.02	-0.05	-0.28	0.0
Other Current Liab	0.07		-0.27	0.25	-0.76	0.89	0.15	0.05	0.2	-0.74	-0.72	-0.35	0.66	0.89	-0.59	-0.73	0.1	0.73	0.27	-0.29	-0.35	0.7	-0.71	-0.93	-0.85	0.27
Total Current Liabilities	-0.6	-0.27		-0.74	-0.35	-0.04	0.61	0.33	-0.53	-0.37	-0.34	0.11	-0.6	-0.27	0.87	-0.38	0.91	0.31	-0.56	0.99	0.11	-0.72	-0.33	0.3	0.33	-0.02
Total Stockholder Equity	0.97	0.25	-0.74		0.22	0.06	-0.52	-0.43	0.96	0.25	0.03	-0.07	0.68	0.21	-0.78	0.26	-0.61	0.0	0.97	-0.73	-0.07	0.67	0.0	-0.24	-0.43	-0.04
Other Liab	0.31	-0.76	-0.35	0.22		-0.89	-0.61	-0.3	0.13	1.0	0.93	0.37	-0.31	-0.67	0.05	1.0	-0.65	-0.87	0.08	-0.31	0.37	-0.18	0.88	0.79	0.7	-0.26
Net Tangible Assets	-0.12	0.89	-0.04	0.06	-0.89		0.32	0.05	0.04	-0.89	-0.78	-0.53	0.63	0.89	-0.45	-0.88	0.35	0.71	0.12	-0.08	-0.53	0.56	-0.72	-0.94	-0.88	0.11
Retained Earnings	-0.46	0.15	0.61	-0.52	-0.61	0.32		0.28	-0.34	-0.63	-0.48	0.3	-0.06	-0.1	0.51	-0.63	0.66	0.43	-0.38	0.63	0.3	-0.38	-0.46	-0.2	-0.27	0.58
Accounts Payable	-0.41	0.05	0.33	-0.43	-0.3	0.05	0.28		-0.35	-0.29	-0.35	0.09	-0.39	-0.09	0.37	-0.3	0.27	0.41	-0.37	0.31	0.09	-0.32	-0.39	-0.08	0.15	-0.05
Cash	0.98	0.2	-0.53	0.96	0.13	0.04	-0.34	-0.35		0.16	-0.11	0.03	0.6	0.1	-0.6	0.16	-0.42	0.14	0.99	-0.51	0.03	0.51	-0.16	-0.19	-0.41	0.05
Other Assets	0.34	-0.74	-0.37	0.25	1.0	-0.89	-0.63	-0.29	0.16		0.92	0.36	-0.3	-0.66	0.02	1.0	-0.68	-0.86	0.11	-0.34	0.36	-0.16	0.87	0.77	0.68	-0.25
Long Term Debt	0.07	-0.72	-0.34	0.03	0.93	-0.78	-0.48	-0.35	-0.11	0.92		0.33	-0.25	-0.6	0.04	0.92	-0.62	-0.97	-0.16	-0.31	0.33	-0.14	0.99	0.71	0.63	-0.23
Good Will	0.08	-0.35	0.11	-0.07	0.37	-0.53	0.3	0.09	0.03	0.36	0.33		-0.2	-0.68	0.38	0.35	-0.11	-0.23	-0.1	0.2	1.0	-0.27	0.24	0.49	0.3	0.34
Other Current Assets	0.53	0.66	-0.6	0.68	-0.31	0.63	-0.06	-0.39	0.6	-0.3	-0.25	-0.2		0.59	-0.84	-0.29	-0.27	0.26	0.64	-0.59	-0.2	0.89	-0.24	-0.7	-0.88	0.05
Other Stockholder Equity	0.0	0.89	-0.27	0.21	-0.67	0.89	-0.1	-0.09	0.1	-0.66	-0.6	-0.68	0.59		-0.65	-0.65	0.1	0.56	0.21	-0.33	-0.68	0.69	-0.55	-0.88	-0.74	-0.04
Total Liab	-0.59	-0.59	0.87	-0.78	0.05	-0.45	0.51	0.37	-0.6	0.02	0.04	0.38	-0.84	-0.65		0.01	0.61	-0.04	-0.66	0.89	0.38	-0.92	0.03	0.62	0.66	0.09
Deferred Long Term Liab	0.34	-0.73	-0.38	0.26	1.0	-0.88	-0.63	-0.3	0.16	1.0	0.92	0.35	-0.29	-0.65	0.01		-0.68	-0.86	0.11	-0.35	0.35	-0.15	0.87	0.76	0.68	-0.25
Short Long Term Debt	-0.54	0.1	0.91	-0.61	-0.65	0.35	0.66	0.27	-0.42	-0.68	-0.62	-0.11	-0.27	0.1	0.61	-0.68		0.57	-0.41	0.9	-0.11	-0.41	-0.59	-0.07	-0.05	-0.03
Preferred Stock Total Equity	-0.03	0.73	0.31	0.0	-0.87	0.71	0.43	0.41	0.14	-0.86	-0.97	-0.23	0.26	0.56	-0.04	-0.86	0.57		0.17	0.29	-0.23	0.19	-0.99	-0.66	-0.58	0.22
Total Current Assets	0.97	0.27	-0.56	0.97	0.08	0.12	-0.38	-0.37	0.99	0.11	-0.16	-0.1	0.64	0.21	-0.66	0.11	-0.41	0.17		-0.55	-0.1	0.57	-0.19	-0.27	-0.47	0.01
Short Term Debt	-0.57	-0.29	0.99	-0.73	-0.31	-0.08	0.63	0.31	-0.51	-0.34	-0.31	0.2	-0.59	-0.33	0.89	-0.35	0.9	0.29	-0.55		0.2	-0.72	-0.31	0.34	0.34	0.01
Intangible Assets	0.08	-0.35	0.11	-0.07	0.37	-0.53	0.3	0.09	0.03	0.36	0.33	1.0	-0.2	-0.68	0.38	0.35	-0.11	-0.23	-0.1	0.2		-0.27	0.24	0.49	0.3	0.34
Common Stock	0.48	0.7	-0.72	0.67	-0.18	0.56	-0.38	-0.32	0.51	-0.16	-0.14	-0.27	0.89	0.69	-0.92	-0.15	-0.41	0.19	0.57	-0.72	-0.27		-0.15	-0.64	-0.71	-0.15
Property Plant Equipment	0.02	-0.71	-0.33	0.0	0.88	-0.72	-0.46	-0.39	-0.16	0.87	0.99	0.24	-0.24	-0.55	0.03	0.87	-0.59	-0.99	-0.19	-0.31	0.24	-0.15		0.66	0.59	-0.24
Short Long Term Debt Total	-0.05	-0.93	0.3	-0.24	0.79	-0.94	-0.2	-0.08	-0.19	0.77	0.71	0.49	-0.7	-0.88	0.62	0.76	-0.07	-0.66	-0.27	0.34	0.49	-0.64	0.66		0.91	-0.25
Net Debt	-0.28	-0.85	0.33	-0.43	0.7	-0.88	-0.27	0.15	-0.41	0.68	0.63	0.3	-0.88	-0.74	0.66	0.68	-0.05	-0.58	-0.47	0.34	0.3	-0.71	0.59	0.91		-0.28
Non Current Assets Total	0.0	0.27	-0.02	-0.04	-0.26	0.11	0.58	-0.05	0.05	-0.25	-0.23	0.34	0.05	-0.04	0.09	-0.25	-0.03	0.22	0.01	0.01	0.34	-0.15	-0.24	-0.25	-0.28

Click cells to compare fundamentals

Context Therapeutics Account Relationship Matchups

Context Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	467.3K	51.3M	38.0M	16.1M	14.5M	22.7M
Other Current Liab	956.0K	1.2M	2.2M	1.8M	2.1M	1.1M
Total Current Liabilities	9.5M	3.0M	3.2M	4.2M	3.8M	6.2M
Total Stockholder Equity	(16.9M)	48.3M	34.8M	11.9M	13.7M	19.8M
Retained Earnings	(18.8M)	(29.3M)	(44.1M)	(68.1M)	(78.3M)	(82.2M)
Accounts Payable	2.7M	1.8M	936.3K	2.4M	2.1M	1.6M
Cash	341.0K	49.6M	35.5M	14.4M	13.0M	20.2M
Other Assets	117.6K	50.4K	0.0	1.0	0.9	0.86
Other Current Assets	8.7K	3.2M	2.4M	1.6M	1.8M	1.4M
Other Stockholder Equity	9.6M	26.2M	78.8M	79.9M	91.9M	96.5M
Total Liab	17.4M	3.0M	3.2M	4.2M	3.8M	3.6M
Total Current Assets	349.7K	51.3M	37.9M	16.0M	18.5M	28.9M
Net Debt	5.6M	(49.6M)	(35.4M)	(14.4M)	(13.0M)	(13.7M)
Non Current Assets Total	117.6K	50.4K	112.3K	15.5K	14.0K	13.3K
Non Currrent Assets Other	117.6K	50.4K	32.8K	(1.0)	(0.9)	(0.85)
Cash And Short Term Investments	341.0K	49.6M	35.5M	14.4M	16.6M	22.0M
Liabilities And Stockholders Equity	467.3K	51.3M	38.0M	16.1M	18.5M	23.3M
Net Invested Capital	(11.0M)	48.3M	34.8M	11.9M	13.7M	18.0M
Net Working Capital	(9.2M)	48.2M	34.6M	11.9M	13.6M	13.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Context Begin Period Cash Flow vs Change In Working Capital Analysis

Begin Period Cash Flow vs Change In Working Capital

Begin Period Cash Flow vs Change In Working Capital Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Change In Working Capital

Context Therapeutics fundamental ratios Correlations

Context Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Context Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Context Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Assets	+ 1.0	Other Liab
Deferred Long Term Liab	+ 1.0	Other Liab
Deferred Long Term Liab	+ 1.0	Other Assets
Intangible Assets	+ 1.0	Good Will
Short Term Debt	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Cash

Property Plant Equipment	- 0.99	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.97	Long Term Debt
Short Long Term Debt Total	- 0.94	Net Tangible Assets
Short Long Term Debt Total	- 0.93	Other Current Liab
Common Stock	- 0.92	Total Liab
Other Assets	- 0.89	Net Tangible Assets